Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes after reduced-intensity conditioning based HCT for dyskeratosis congenita

Akshay Sharma • 2 Feb 2021
TCT 2021
General Busulfan

Dyskeratosis congenita is a multisystem disorder caused by impaired telomere maintenance. In this interview, Akshay Sharma, MBBS, of St. Jude Children’s Research Hospital, Memphis, TN, outlines the outcomes of patients with dyskeratosis congenita treated with reduced-intensity conditioning based hematopoietic cell transplantation (HCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Akshay Sharma

The risk of developing leukemia after lentiviral gene therapy
5:44
The risk of developing leukemia after lentiviral gene therapy
Akshay Sharma • 9 Apr 2025
The role of palliative care in patients with sickle cell disease undergoing SCT or gene therapy
1:58
The role of palliative care in patients with sickle cell disease undergoing SCT or gene therapy
Akshay Sharma • 9 Apr 2025
The main benefits and challenges of gene therapy for sickle cell disease
4:08
The main benefits and challenges of gene therapy for sickle cell disease
Akshay Sharma • 9 Apr 2025
Is there a risk of infection and a need for re-vaccination after gene therapy?
3:23
Is there a risk of infection and a need for re-vaccination after gene therapy?
Akshay Sharma • 9 Apr 2025

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals